Department of Gastroenterology, Hepatology, and Nutrition, Shanghai Children's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gut Microbiota and Metabolic Research Center, Institute of Pediatric Infection, Immunity and Critical Care Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
J Food Sci. 2024 May;89(5):3078-3093. doi: 10.1111/1750-3841.17057. Epub 2024 Apr 11.
Human milk contains a variety of microorganisms that exert benefit for human health. In the current study, we isolated a novel Lactobacillus gasseri strain named Lactobacillus gasseri (L. gasseri) SHMB 0001 from human milk and aimed to evaluate the probiotic characteristics and protective effects on murine colitis of the strain. The results showed that L. gasseri SHMB 0001 possessed promising potential probiotic characteristics, including good tolerance against artificial gastric and intestinal fluids, adhesion to Caco-2 cells, susceptibility to antibiotic, no hemolytic activity, and without signs of toxicity or infection in mice. Administration of L. gasseri SHMB 0001 (1 × 10 CFU per gram of mouse weight per day) reduced weight loss, the disease activity index, and colon shortening in mice during murine colitis conditions. Histopathological analysis revealed that L. gasseri SHMB 0001 treatment attenuated epithelial damage and inflammatory infiltration in the colon. L. gasseri SHMB 0001 treatment increased the expression of colonic occludin and claudin-1 while decreasing the expression of pro-inflammatory cytokine genes. L. gasseri SHMB 0001 modified the composition and structure of the gut microbiota community and partially recovered the Clusters of Orthologous Groups (COG) and Kyoto Encyclopedia of Genes and Genomes (KEGG) metabolic pathways altered by dextran sulfate sodium (DSS). Overall, our results indicated that the human breast milk-derived L. gasseri SHMB 0001 exhibited promising probiotic properties and ameliorative effect on DSS-induced colitis in mice. L. gasseri SHMB 0001 may be applied as a promising probiotic against intestinal inflammation in the future. PRACTICAL APPLICATION: L. gasseri SHMB 0001 isolated from human breast milk showed good tolerance to gastrointestinal environment, safety, and protective effect against DSS-induced mice colitis via enforcing gut barrier, downregulating pro-inflammatory cytokines, and modulating gut microbiota. L. gasseri SHMB 0001 may be a promising probiotic candidate for the treatment of intestinal inflammation.
人乳中含有多种对人类健康有益的微生物。在本研究中，我们从人乳中分离出一种新型的格氏乳杆菌，命名为人乳格氏乳杆菌（Lactobacillus gasseri）SHMB 0001，并旨在评估该菌株的益生菌特性及其对小鼠结肠炎的保护作用。结果表明，L. gasseri SHMB 0001 具有良好的益生菌特性，包括对人工胃液和肠液的良好耐受性、对 Caco-2 细胞的黏附能力、对抗生素的敏感性、无溶血活性，以及在小鼠中无毒性或感染迹象。在小鼠结肠炎条件下，给予 L. gasseri SHMB 0001（每天每克小鼠体重 1×10 CFU）可减轻体重减轻、疾病活动指数和结肠缩短。组织病理学分析显示，L. gasseri SHMB 0001 治疗可减轻结肠上皮损伤和炎症浸润。L. gasseri SHMB 0001 治疗可增加结肠紧密连接蛋白和闭合蛋白-1 的表达，同时降低促炎细胞因子基因的表达。L. gasseri SHMB 0001 可改变肠道微生物群落的组成和结构，并部分恢复葡聚糖硫酸钠（DSS）改变的 Clusters of Orthologous Groups（COG）和 Kyoto Encyclopedia of Genes and Genomes（KEGG）代谢途径。总的来说，我们的研究结果表明，来源于人乳的格氏乳杆菌 SHMB 0001 具有良好的益生菌特性，并可改善 DSS 诱导的小鼠结肠炎。L. gasseri SHMB 0001 可能在未来被用作一种有前途的治疗肠道炎症的益生菌。实际应用：从人乳中分离出的 L. gasseri SHMB 0001 对胃肠道环境具有良好的耐受性、安全性，并通过增强肠道屏障、下调促炎细胞因子和调节肠道微生物群来预防 DSS 诱导的小鼠结肠炎。L. gasseri SHMB 0001 可能是治疗肠道炎症的一种有前途的益生菌候选物。
Microbiome Res Rep. 2024-6-17
Zotero 插件